Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06955143
Recruiting Observational

A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome

NCT06955143 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Phase
Observational
Started
2025-03-11
Last updated
2025-07-25

Condition(s) studied

Acute Coronary SyndromeChronic Coronary Syndrome

Study summary

The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are:

The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: For ACS group STEMI * cTn\>99th ULN or CK-MB\>99th ULN * ST-segment elevation with a convex upward morphology * in conjunction with one or more of the following conditions: persistent ischemic chest pain; echocardiographic evidence of abnormal segmental ventricular wall motion; or abnormal coronary angiography findings. NSTEMI * cTn\>99th ULN or CK-MB\>99th ULN * accompanied by one or more of the following situations: persistent ischemic chest pain; new ST-segment depression or low and inverted T waves; echocardiography showing segmental ventricular wall motion abnormalities; abnormal coronary angiography. UA * cTn normal * ischemic chest pain with an electrocardiogram showing transient ST-segment depression or flattened and inverted T waves * evidence of coronary artery stenosis (e.g., CTA demonstrating ≥ 50% stenosis) For CCS group * Clinical Diagnosis Consistent with CCS Categories, meet any one of the following clinical scenarios: Stable Angina Pectoris, Ischemic Cardiomyopathy, Post-ACS Stable Phase, Long-Term CAD Management, Vasospastic or Microvascular Disease, Asymptomatic CAD * Laboratory and Imaging Confirmation: Resting ECG without ST-segment elevation or dynamic changes (excluding ACS), cTn normal or stable (no acute myocardial injury), ≥50% luminal stenosis in ≥1 epicardial coronary artery For control group * Patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy Exclusion Criteria: * Lactating or pregnant women * Patients with malignant neoplasms * Severe hepatic/renal dysfunction * Severe hematological disorders * Autoimmune diseases

Primary outcome measure(s)

  • circulating fibroblast growth factors (FGFs) levels — within 24 hours of admission to the hospital
    examining the circulating fibroblast growth factors levels in the peripheral venous blood of the participants
  • circulating inflammatory cytokines levels — within 24 hours of admission to the hospital
    examining the circulating inflammatory cytokines levels in the peripheral venous blood of the participants
  • circulating chemokines levels — within 24 hours of admission to the hospital
    examining the circulating chemokines levels in the peripheral venous blood of the participants
  • circulating Cytochrome C level — within 24 hours of admission to the hospita
    examining the circulating cytochrome c levels in the peripheral venous blood of the participants
  • circulating mitochondrial DNA levels — within 24 hours of admission to the hospital
    examining the circulating mitochondrial DNA levels in the peripheral venous blood of the participants
  • circulating malondialdehyde levels — within 24 hours of admission to the hospital
    examining the circulating malondialdehyde levels in the peripheral venous blood of the participants

Trial sites (1)

FacilityCityRegionStatus
Lishui Central Hospital Lishui Zhejiang Recruiting

More Second Affiliated Hospital of Wenzhou Medical University trials in China

Effect of FPCA on Incidence of Emergency Delirium in Children After Surgery Recruiting
A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents Enrolling by invitation
Effect of Adenotonsillectomy on Spinal Curve Magnitude in Children With Sleep-Disordered Breathing Recruiting
MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis Enrolling by invitation
Effect of Sevoflurane on Sweat Threshold in Children of Different Ages Starting soon

Other trials for the same condition

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention Recruiting
1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon Active, not recruiting
Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol Starting soon
Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome Recruiting
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06955143 on ClinicalTrials.gov ↗ ← All trials in China